News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Breakthrough Therapy designation for pain associated with DPN granted by FDA
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Subscribe To Our Newsletter & Stay Updated
